ArticleNPJ digital medicine2026
External validation of ECG artificial intelligence for emergency and cardiac assessment across a large-scale U.S. healthcare system.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects.Signal transduction and targeted therapy · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An ECG-based artificial intelligence (AI) model was previously developed to generate ten digital biomarkers for emergency and cardiac assessment and is currently deployed in clinical practice in Korea (ECG Buddy, ARPI Inc.). Its external validity within U.S. healthcare settings has not been established. This study evaluated model performance using a large-scale, multi-center U.S. dataset via the Mayo Clinic Platform (MCP) Discover. Two validation cohorts were assessed: an emergency-diagnosis cohort (mortality, AMI, STEMI and equivalents, hyperkalemia, pulmonary edema) using initial ED ECGs, and a cardiac-function cohort (left and right ventricular systolic dysfunction, pulmonary hypertension, hemodynamically significant pericardial effusion) anchored to echocardiography or right-heart catheterization. The primary objective was non-inferiority of the Area Under the Receiver Operating Characteristic Curve (AUC) relative to prespecified benchmarks. Across ten target conditions, AUCs ranged from 0.883 to 0.949; all met non-inferiority criteria. Performance was consistent across sex and age strata. In a paired subset (N = 1368), ECG-AI outperformed initial troponin T for AMI (AUC 0.920 vs. 0.878) and STEMI equivalents (AUC 0.932 vs. 0.736; all P < 0.001). These findings support the model's potential for ECG-based screening and triage, and provide a foundation for prospective evaluation of calibration, clinical integration, and impact across diverse populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.